Carrier strategies boost the application of CRISPR/Cas system in gene therapy. Issue 2 (15th March 2022)

• Record Type: Journal Article
• Authors: Xu, Zunkai; Wang, Qingnan; Zhong, Haiping; Jiang, Yaoyao; Shi, Xiaoguang; Yuan, Bo; Yu, Na; Zhang, Shubiao; Yuan, Xiaoyong; Guo, Shutao; Yang, Yang
• Is Part Of: Exploration. Volume 2:Issue 2(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-03-15
• Subjects: CRISPR -- drug delivery -- gene therapy -- genome editing -- nanomaterials; Ultrastructure (Biology); Periodicals; 620.5
• DOI: 10.1002/EXP.20210081
• Languages: English
• ISSNs: 2766-8509

Abstract

Abstract: Emerging clustered regularly interspaced short palindromic repeat/associated protein (CRISPR/Cas) genome editing technology shows great potential in gene therapy. However, proteins and nucleic acids suffer from enzymatic degradation in the physiological environment and low permeability into cells. Exploiting carriers to protect the CRISPR system from degradation, enhance its targeting of specific tissues and cells, and reduce its immunogenicity is essential to stimulate its clinical applications. Here, the authors review the state‐of‐the‐art CRISPR delivery systems and their applications, and describe strategies to improve the safety and efficacy of CRISPR mediated genome editing, categorized by three types of cargo formats, that is, Cas: single‐guide RNA ribonucleoprotein, Cas mRNA and single‐guide RNA, and Cas plasmid expressing CRISPR/Cas systems. The authors hope this review will help develop safe and efficient nanomaterial‐based carriers for CRISPR tools. Abstract : This review mainly focuses on the state‐of‐the‐art CRISPR delivery systems and their applications, categorized by three types of cargo formats, that is, Cas: single‐guide RNA ribonucleoprotein, Cas mRNA and single‐guide RNA, and Cas plasmid expressing CRISPR/Cas systems.